Raloxifene HCL is an oral selective estrogen receptor modulator (SERM)
that has estrogenic actions on bone and anti-estrogenic actions on the
uterus and breast. Raloxifene HCL is used in the prevention of
osteoporosis in postmenopausal women.
Raloxifene powder
Fuction of Raloxifene HCL
Raloxifene HCL is used to prevent and treat osteoporosis (condition in
which the bones become thin and weak and break easily) in women who have
undergone menopause (change of life; end of menstrual periods).
Raloxifene HCL is also used to decrease the risk of developing invasive
breast cancer (breast cancer that has spread outside of the milk ducts
or lobules into the surrounding breast tissue) in women who are at high
risk of developing this type of cancer or who have osteoporosis.
Raloxifene HCL cannot be used to treat invasive breast cancer or to
prevent invasive breast cancer from coming back in women who have
already had the condition.
Raloxifene HCL also cannot be used to decrease the risk of developing
non-invasive breast cancer. Raloxifene HCL is in a class of medications
called selective estrogen receptor modulators (SERMs). Raloxifene HCL
prevents and treats osteoporosis by mimicking the effects of estrogen (a
female hormone produced by the body) to increase the density
(thickness) of bone.
Raloxifene HCL decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue.
Raloxifene HCL may stop the development of tumors that need estrogen to grow.
Application of Raloxifene HCL
Raloxifene Hydrochloride is an active pharmaceutical ingredient used to
prevent osteoporosis in postmenopausal women and to reduce the risk of
invasive breast cancer in postmenopausal women with osteoporosis and in
postmenopausal women at high risk for invasive breast cancer.
The Wall